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Abstract
The Forkhead Box m1 (Foxm1) protein is induced in a majority of human non-small cell lung cancers and its expression is
associated with poor prognosis. However, specific requirements for the Foxm1 in each cell type of the cancer lesion remain
unknown. The present study provides the first genetic evidence that the Foxm1 expression in respiratory epithelial cells is
essential for lung tumorigenesis. Using transgenic mice, we demonstrated that conditional deletion of Foxm1 from lung
epithelial cells (epFoxm1
2/2 mice) prior to tumor initiation caused a striking reduction in the number and size of lung
tumors, induced by either urethane or 3-methylcholanthrene (MCA)/butylated hydroxytoluene (BHT). Decreased lung
tumorigenesis in epFoxm1
2/2 mice was associated with diminished proliferation of tumor cells and reduced expression of
Topoisomerase-2a (TOPO-2a), a critical regulator of tumor cell proliferation. Depletion of Foxm1 mRNA in cultured lung
adenocarcinoma cells significantly decreased TOPO-2a mRNA and protein levels. Moreover, Foxm1 directly bound to and
induced transcription of the mouse TOPO-2a promoter region, indicating that TOPO-2a is a direct target of Foxm1 in lung
tumor cells. Finally, we demonstrated that a conditional deletion of Foxm1 in pre-existing lung tumors dramatically reduced
tumor growth in the lung. Expression of Foxm1 in respiratory epithelial cells is critical for lung cancer formation and TOPO-
2a expression in vivo, suggesting that Foxm1 is a promising target for anti-tumor therapy.
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Introduction
Lung cancer is the leading cause of cancer-related deaths in men
and women in the United States [1]. It has a high mortality because it
is difficult to detect early and is frequently resistant to available
chemotherapy and radiotherapy. Therefore, identification of proteins
regulating the proliferation of lung tumor cells will provide novel
targets for diagnosis and treatment of human lung cancer. Lung
cancer is classified into small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC). Adenocarcinoma, the most common type
of NSCLC, is frequently associated with gain of function mutations in
the K-Ras oncogene [2,3], activation of c-myc protein, as well as the
loss of function mutations in the tumor suppressor gene p53 [4,5].
Activating mutations in K-Ras also occur in the majority of
spontaneous and chemically induced lung tumors in mice [6].
The Foxm1 transcription factor is broadly expressed in actively
proliferating cells of all origins [7]. Activation of the Ras-MAPK
signaling pathway drives cell cycle progression by regulating the
temporal expression of Cyclin regulatory subunits, that activate their
corresponding Cyclin-dependent kinases (Cdk) through complex
formation. Cdk/cyclin complexes phosphorylate and activate a
variety of cell cycle regulatory proteins, including Foxm1 [2,5,8].
Activated MAPK (ERK) kinase directly phosphorylates the Foxm1
protein, contributing to its transcriptional activation [9]. Foxm1
directly stimulates the transcription of genes essential for progression
into DNA replication and mitosis, including cyclin B1, Cdc25B
phosphatase, Aurora B kinase and Polo-like kinase 1 [10]. Foxm1
2/2 mice
exhibit embryonic lethality due to severe proliferation defects in the
developing heart, liver, and blood vessels [11].
Consistent with an important role of Foxm1 in cell cycle
progression, increased expression of Foxm1 was found in human
lung adenocarcinomas and squamous cell carcinomas, prostate
adenocarcinomas, basal cell carcinomas, intrahepatic cholangio-
carcinomas, anaplastic astrocytomas and glioblastomas, infiltrating
ductal breast carcinomas, as well as in many other solid tumors
(reviewed in [10,12,13,14]). Inhibition of Foxm1 in cultured tumor
cells with either siRNA transfection or pharmacological agents
caused a cell cycle arrest [15,16,17,18,19]. Previous studies with
Mx-Cre Foxm1
fl/fl mice demonstrated that deletion of Foxm1 from
all cell types of the body caused a significant reduction in number
and size of lung adenomas induced by urethane [20]. Further-
more, over-expression of Foxm1 in all cell types in Rosa26-Foxm1
transgenic mice significantly increased the number and size of lung
tumors induced by MCA/BHT lung tumor induction/promotion
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of Foxm1 in lung tumorigenesis, specific requirements for this
transcription factor in different populations of respiratory cells
remain unknown. Since lung cancer lesions contain a heteroge-
neous population of cells, that includes tumor cells, originated
from genetically modified epithelial cells, and different inflamma-
tory and stromal cells [22], it is important to know the cell
autonomous role of Foxm1 during lung tumorigenesis. In the
present study, transgenic mice were generated in which the Foxm1
gene was conditionally deleted in lung epithelial cells (epFoxm1
2/2
mice) either prior to the initiation of chemically-induced lung
cancer, or during cancer progression/expansion. Deletion of
Foxm1 from epithelial cells caused a striking decrease in the
number and size of lung adenomas. Decreased lung tumorigenesis
in epFoxm1
2/2 mice was associated with diminished proliferation
of tumor cells and reduced expression of Topoisomerase-2a (TOPO-
2a), a critical regulator of tumor cell proliferation. Depletion of
Foxm1 mRNA in cultured lung adenocarcinoma cells significantly
decreased TOPO-2a mRNA and protein. Foxm1 directly bound to
and induced transcription of the mouse TOPO-2a promoter
region, indicating that TOPO-2a is a direct transcriptional target of
Foxm1. Taken together, our data demonstrate that Foxm1
expression in respiratory epithelial cells is critical for expansion
of lung cancer and TOPO-2a expression in lung tumor cells.
Results
Conditional deletion of Foxm1 transcription factor in
lung epithelial cells
To determine the role of Foxm1 in epithelial cells during
formation of lung tumors, we generated triple-transgenic mice
containing LoxP-flanked exons 4–7 of the Foxm1 gene (Foxm1
fl/fl),
the SP-C–rtTA
tg/2 and the TetO-Cre
tg/2 transgenes (SP-C–rtTA
tg/2/
TetO-Cre
tg/2/Foxm1
fl/fl or epFoxm1
fl/fl mice). To induce Cre
expression in lung epithelial cells, Dox was given to the adult mice
in water for 4 weeks. Previous studies demonstrated that using this
protocol, Cre-mediated recombination occurs in type II epithelial
cells and Clara cells of the adult lung [23]. In the presence of Dox,
the reverse tetracycline transactivator (rtTA) binds to the TetO
promoter and induces expression of Cre recombinase, deleting
exons 4–7, which encode DNA binding and transcriptional
activation domains of the Foxm1 protein (Fig. 1A); thus, lung
epithelial-specific Foxm1 knockout mice (epFoxm1
2/2) are generated.
Consistent with previous studies, Cre protein was detected in
epithelial type II (Fig. 1B) and Clara cells (Fig. 1C) of Dox-treated
epFoxm1
2/2 mice but not in control Foxm1
fl/fl mice (Fig. 1B–C). No
morphological changes were observed in either epFoxm1
2/2 or
control Foxm1
fl/fl lungs after 4 weeks of Dox treatment (Fig. 1D).
Thus, the Foxm1 deletion from adult lungs does not alter lung
structure.
Foxm1 deletion from respiratory epithelial cells reduces
numbers and sizes of lung tumors
To determine the role of Foxm1 in epithelial cells during
formation of lung tumors, experimental epFoxm1
fl/fl and control
male mice were given Dox for 4 weeks. Control groups included
Dox-treated Foxm1
fl/fl male mice and epFoxm1
fl/+mice, as well as
epFoxm1
fl/fl transgenic mice without Dox treatment. Mice were
subjected to 6 weekly urethane injections to induce lung tumors
(Fig. 2A). Dox treatment was continued for additional 20 or 28
weeks after the first urethane injection. In this model, deletion of
Foxm1 from lung epithelial cells was induced prior to the initiation
of lung tumorigenesis.
The total number of urethane-induced lung tumors was
decreased approximately 5-fold in epFoxm1
2/2 (epFoxm1
fl/fl+Dox)
mice compared to all control groups (Fig. 2B and data not shown).
Numbers of large (.2 mm), medium (1–2 mm) and small-sized
(,1 mm) tumors were significantly decreased in epFoxm1
2/2 mice
at both 20 and 28 weeks after the first urethane injection (Fig. 2C–
D and Fig. 3A). Histological examination of H&E-stained sections
confirmed the reduced size of lung tumors from epFoxm1
2/2 mice
and showed that these tumors displayed morphological charac-
teristics of lung adenomas (Fig. 3B). To identify the origin of the
lung tumor cells, the immunohistochemical staining was per-
formed using antibodies against either surfactant protein C (SPC),
a type II lung alveolar epithelial cell marker, or Clara cell specific
protein (CCSP), Clara cells marker. All tumors in control and
epFoxm1
2/2 mice were SPC- positive (Fig. 3C), indicating that
they developed from alveolar type II epithelial cells. No CCSP-
positive tumors were found in either epFoxm1
2/2 or control
epFoxm1
fl/fl lungs (Fig. 3D). Interestingly, epFoxm1
2/2 tumors
maintained normal expression levels of TTF-1, a lung epithelial-
specific transcription factor, implicated in controlling cellular
proliferation during embryogenesis and formation of non-small
cell lung cancer [24].
Foxm1 deletion from respiratory epithelial cells
diminishes tumor cell proliferation
To address the efficiency of deletion of the Foxm1
fl/fl allele from
lung tumors, Foxm1 mRNA was examined by in situ hybridization
of lung paraffin sections. Consistent with efficient Cre-mediated
recombination, Foxm1 mRNA was decreased in lung tumors from
epFoxm1
2/2 mice compared to Foxm1
fl/fl mice (Fig. 4A and 4B).
Furthermore, numbers of KI-67 positive cells were significantly
reduced in epFoxm1
2/2 tumors (Fig. 4C–D and 4E). We did not
observe any differences in the number of apoptotic cells in the
tumors from control and epFoxm1
2/2 mice (data not shown).
Altogether, these results indicate that Foxm1 deletion from type II
lung epithelial cells is sufficient to reduce proliferation of tumor
cells in vivo and decrease urethane-mediated lung tumorigenesis.
Tumors from epFoxm1
2/2 mice demonstrate altered
expression of genes important for cellular proliferation
and lung tumorigenesis
To identify new molecular targets of Foxm1 in respiratory
epithelial cells, lung tumors were dissected from control and
urethane-treated mice and then used to prepare total RNA. Even
with the contribution of non-tumor cell RNA (endothelial cells,
macrophages, fibroblasts), the Real-time RT-PCR analysis
revealed decreased Foxm1 mRNA levels in epFoxm1
2/2 tumors
compared to control Foxm1
fl/fl tumors (Fig. 5A). Foxm1 deficiency
in epFoxm1
2/2 tumors was associated with decreased mRNA levels
of cyclin B1 (Fig. 5A), a known transcriptional target for Foxm1
[25]. Expression of several genes important for cellular prolifer-
ation and lung carcinogenesis was also studied, including c-Myc,
cyclin D1, TOPO-2a, TCF4, VEGF-A, TTF-1, PPARc and PPARa.
While TOPO-2a and PPARc mRNA were decreased in lung
tumors from epFoxm1
2/2 mice, PPARa mRNAs was significantly
increased (Fig. 5A). No changes were found in the mRNA
expression of c-Myc, cyclin D1, TCF4, TTF-1 and VEGF-A genes
(Fig. 5B).
Foxm1 deletion after tumor initiation decreases lung
tumor expansion/progression
Having established that deletion of Foxm1 from lung epithelial
cells prior to tumor initiation significantly reduced lung tumori-
Foxm1 in Lung Tumors
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6609Figure 1. Conditional deletion of Foxm1 transcription factor in lung epithelial cells. A. Breeding strategy for conditional expression of rtTA
in the respiratory epithelium to delete the Foxm1 floxed exons in vivo. Dox-induced expression of Cre-recombinase causes the deletion of exon 4–7 of
Foxm1 gene (epFoxm1
2/2 mice). B–C. Specific expression of Cre in lung epithelium. Lungs from epFoxm1
2/2 and control Foxm1
fl/fl mice, that were
given Dox in water for 4 weeks, were fixed, paraffin-embedded, sectioned, and stained with Cre antibody (dark brown nuclei) and then
counterstained with nuclear fast red (red nuclei). Cre expression was observed in type II lung epithelial cells (B) and Clara cells (C), but not in
mesenchymal cells of Dox-treated epFoxm1
2/2 lungs. Cre recombinase was not detected in control Foxm1
fl/fl lungs. D. Conditional expression of Cre
in lung epithelial cells does not alter the lung morphology. Paraffin sections from Dox-treated epFoxm1
2/2 and control Foxm1
fl/fl lungs were stained
with hematoxylin and eosin (H&E). Normal lung alveoli and bronchi were observed in control Foxm1
fl/fl and epFoxm1
2/2 mice. Magnifications:6200
(B–C) and 650 (D).
doi:10.1371/journal.pone.0006609.g001
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whether Foxm1 was required during progression/expansion of
lung tumors in vivo. Lung tumors in epFoxm1
fl/fl and control
Foxm1
fl/fl mice were induced by six urethane injections. One week
after the last urethane injection, Dox-treatment was initiated and
continued until the completion of the experiment at 20 or 28
weeks (Fig. 6A). Thus, Foxm1 deletion occurs after initiation of
lung tumors. A significant decrease in the number of lung tumors
was observed in Dox-treated epFoxm1
2/2 mice compared to either
Dox-treated Foxm1
fl/fl mice or epFoxm1
fl/fl mice without Dox
treatment (Fig. 6B). These results demonstrate that Foxm1
expression in the pulmonary epithelium is required for the
progression/expansion of urethane-induced lung cancer.
Foxm1 is essential for lung tumorigenesis induced by
MCA/BHT
To demonstrate that the established critical role of Foxm1 in
lung epithelial cells is not limited only to urethane mediated
tumorigenesis, we used another experimental mouse model of lung
cancer: two-step lung tumor initiation/promotion using 3-
methylcholanthrene (MCA)/butylated hydroxytoluene (BHT).
Lung tumors in epFoxm1
2/2 and control male mice were induced
by a single injection of MCA, a carcinogen found in tobacco
smoke [26,27]. Starting one week after MCA injection, mice were
subjected to weekly injections of BHT for 6 consecutive weeks to
promote formation of lung tumors by causing chronic pulmonary
inflammation and remodeling of the lung [26]. To induce Foxm1
deletion prior to tumor initiation, Dox was administered for 4
weeks prior to MCA injection (Fig. 7A). To avoid negative effects
of Dox on lung inflammation, we did not administer Dox to mice
during MCA/BHT injections. In another series of experiments,
Dox was given one week after BHT treatment, causing Foxm1
deletion after tumor initiation (Fig. 7B). Both types of experiments
demonstrated that epFoxm1
2/2 mice were resistant to lung
tumorigenesis as demonstarated by comparison of tumor numbers
in Foxm1-deficient mice to either control Foxm1
fl/fl mice, or triple
transgenic epFoxm1
fl/fl mice without Dox treatment (Fig. 7A and
7B). The epFoxm1
2/2 lungs displayed only few microscopic tumor
lesions. Immunohistochemistry demonstrated that decreased
numbers and size of lung tumors in epFoxm1
2/2 lungs were
associated with reduced Foxm1 expression (Fig. 8A–F) and
decreased proliferation in tumor regions (Fig. 8G–L). Consistent
with urethane experiments, MCA/BHT treated epFoxm1
2/2 lungs
displayed decreased TOPO-2a, cyclin B1 and PPARc mRNAs,
confirming a critical role of Foxm1 in the regulation of these genes
in lung tumor cells in vivo (Fig. 7C). Altogether, our results
demonstrate that Foxm1 in epithelial cells plays a critical role
during chemically-induced and inflammation-mediated lung
tumorigenesis.
TOPO-2a is a direct target of Foxm1 transcriptional factor
in lung epithelial cells
Our in vivo experiments suggested that Foxm1 regulated lung
epithelial genes essential for lung cancer formation. To determine
whether Foxm1 regulates expression of these genes in vitro, A549
human lung adenocarcinoma cells were transfected with short
Figure 2. Foxm1 deletion from lung epithelial cells prior to tumor initiation reduced the number and size of urethane-induced lung
tumors. Experimental epFoxm1
2/2 (epFoxm1
fl/fl+Dox) and control Foxm1
fl/fl (Foxm1
fl/fl+Dox) mice were given Dox in water to activate Cre expression
prior to induction of lung tumors by multiple urethane injections as described in Materials and Methods. The second control group of epFoxm1
fl/fl
mice was given regular water (epFoxm1
fl/fl – Dox; this mouse group was used as a control for Dox-independent recombination). All three groups of
mice received six weekly injections of urethane to induce lung tumors. A. Experimental design of conditional deletion of Foxm1
fl/fl prior to tumor
induction. B. Lung tumors from experimental epFoxm1
2/2 (epFoxm1
fl/fl+Dox) mice and control mice were counted and measured using a dissecting
microscope at 20 weeks and 28 weeks after the first urethane injection. Deletion of Foxm1 prior to tumor induction significantly reduced (p,0.05) the
total number of lung tumors at both time points. C–D. The tumor diameters were significantly reduced (p,0.05) at 20 weeks (C) and 28 weeks (D)
after tumor induction. Mean number of tumors per lung (6SD) and tumor sizes were calculated from n=12 mouse lungs per group.
doi:10.1371/journal.pone.0006609.g002
Foxm1 in Lung Tumors
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2/2 and control Foxm1
fl/fl mice, that were given
Dox in water starting 4 weeks before urethane injections, were photographed and fixed 28 weeks after the first urethane injection. Lung sections
were used either for H&E staining or immunohistochemistry. A. Photographs of control Foxm1
fl/fl mouse lungs (left lungs) depict lung tumors 28
weeks after the first urethane injection. Experimental epFoxm1
2/2 mice were resistant to tumor induction (right lungs), showing no visible tumors.
B. H&E staining demonstrates a reduction in the size of lung tumors (Tu) in epFoxm1
2/2 mouse lungs. C. Lung tumors in control and epFoxm1
2/2 are
positive for SPC, a marker of type II lung epithelial cells. D. Lung tumors in control and epFoxm1
2/2 are negative for CCSP, a marker of Clara cells.
E. Similar expression of TTF-1 transcription factor in epFoxm1
2/2 and control Foxm1
fl/fl tumors. Magnification: A panels, 106; B–E panels, 1006.
doi:10.1371/journal.pone.0006609.g003
Foxm1 in Lung Tumors
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(siFoxm1) or with mutant control siFoxm1 [13]. Forty-eight hours
after siRNA transfection, total RNA was prepared from the A549
cells and analyzed for Foxm1 expression by qRT-PCR. siFoxm1
transfection efficiently reduced Foxm1 mRNA, also inhibiting the
expression of Foxm1-target cyclin B1 gene (Fig. 9A). Consistent
with our in vivo studies (Fig. 5A), Foxm1-depletion in vitro
significantly decreased TOPO-2a mRNA, whereas PPARa mRNA
was increased (Fig. 9A). Furthermore, protein levels of TOPO-2a
were decreased after Foxm1 depletion in A549 cells as
demonstrated by Western blot analysis (Fig. 9B).
Lung epithelial-specific ablation of Foxm1 both in vivo and in vitro
resulted in significant decrease in TOPO-2a mRNA expression,
which suggests that Foxm1 plays direct or indirect role in the
regulation of TOPO-2a gene expression. Since TOPO-2a is a
prominent target for anti-tumor therapy [28] due to its critical role
in tumor cell proliferation, we focused our next experiments to
determine whether TOPO-2a gene is a direct transcriptional target
of Foxm1. Three potential Foxm1 protein binding sites were
identified in the –1.5 Kb promoter region of the mouse TOPO-2a
gene (Fig. 9C). We next used Chromatin Immunoprecipitation
(ChIP) assays to determine whether Foxm1 protein directly binds
to the -1.5 Kb TOPO-2a promoter region in the context of
endogenous DNA. The cross-linked and sonicated chromatin from
untransfected mouse lung epithelial 15 (MLE-15) cells or MLE-15
cells transfected with Foxm1-specific siRNA was immunoprecip-
Figure 4. Foxm1 deletion from respiratory epithelial cells diminishes tumor cell proliferation. Lungs from epFoxm1
2/2 and control
Foxm1
fl/fl mice, that were given Dox in water starting 4 weeks before urethane injections, were photographed and fixed 28 weeks after the first
urethane injection. Lung sections were used either for in situ hybridization or immunohistochemistry. A–B. In situ hybridization demonstrates that
Foxm1 mRNA is selectively decreased in lung tumors of epFoxm1
2/2 lungs (B) versus control epFoxm1
fl/fl mice (A). C–D. Diminished cell proliferation
in epFoxm1
2/2 lung tumors (D) is shown using Ki-67 antibody. E. Decreased number of Ki-67-positive cells in epFoxm1
2/2 mouse lungs. Ki-67-
positive cells were counted in ten random microscope fields from tumor regions of control and epFoxm1
2/2 lungs (mean+s.d.). Magnification: A
panels, 106; B–D panels, 1006.
doi:10.1371/journal.pone.0006609.g004
Foxm1 in Lung Tumors
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control antibodies. Binding of TOPO-2a promoter DNA associated
with the IP chromatin was determined by qRT-PCR with primers
specific to the potential Foxm1-binding region in mouse TOPO-2a
promoter. Foxm1 protein specifically bound to the TOPO-2a
promoter region as demonstrated by the ability of siFoxm1 to
reduce binding of Foxm1 protein to TOPO-2a promoter DNA
(Fig. 9D). To determine whether the Foxm1-binding sites were
transcriptionally active, co-transfection experiments were per-
formed using CMV-Foxm1b expression vector [29] and luciferase
(LUC) reporter construct driven by TOPO-2a promoter region.
Co-transfection of the CMV-Foxm1b expression vector signifi-
cantly increased expression of the –1.5 Kb TOPO-2a reporter
plasmid when compared to CMV-empty vector (Fig. 9E),
indicating that Foxm1 is a transcriptional activator of TOPO-2a
gene. These results demonstrate that Foxm1 directly binds to and
transcriptionally activates the mouse TOPO-2a promoter region,
indicating that TOPO-2a is a direct Foxm1 target gene.
Discussion
Existing treatments for lung cancer have not significantly
improved survival, leading to a critical need for new approaches.
The important role of Foxm1 in lung cancer has already been
established. However, our basic understanding of its role in
different cell populations of the tumor is limited. Furthermore, the
molecular mechanisms whereby cell autonomous Foxm1 expres-
sion regulates lung tumorigenesis remain to be established.
The important contribution of the current study is the
establishment of the critical role of Foxm1 in respiratory epithelial
cells during formation of lung cancer. The conditional deletion of
Foxm1 from lung epithelial cells strikingly decreased the
development of lung tumors in mice, diminished proliferation of
tumor cells and reduced the expression of cyclin B1 and TOPO-2a.
Foxm1 deficiency was also associated with increased expression of
PPAR-a. Altogether, these observations provide new insight into a
cell autonomous role of Foxm1 in the pathogenesis of pulmonary
adenocarcinoma, and identify the Foxm1 transcription factor as a
potential target for treatment of human lung cancer.
Increased Foxm1 levels were found in numerous types of
human tumors, including non small cell lung cancer [14,20]. Our
previous studies demonstrated that when the Foxm
fl/fl allele was
deleted in all cell types using Mx-Cre transgene, the numbers and
sizes of lung adenomas following urethane exposure were reduced
[20]. On the contrary, over-expression of Foxm1 in all cell types
using Rosa 26 promoter led to striking increase in the numbers
Figure 5. Deletion of Foxm1 influenced the expression of several genes. Microdissected tumors from control Foxm1
fl/fl+Dox or experimental
epFoxm1
fl/fl+Dox mouse lungs (n=3 mice per group) were used to prepare total RNA for Quantitative real-time RT-PCR. A. Decreased Foxm1, TOPO-
2a, cyclin B1, PPARc and increased PPARa mRNAs were observed in epFoxm1
2/2 (epFoxm1
fl/fl+Dox) lung tumors. B. No changes were found in the
expression of the c-Myc, TCF-4, cyclin D1, TTF-1 and VEGF-A genes. b-actin mRNA was used for normalization. A p value,0.05 is shown with asterisk (*).
doi:10.1371/journal.pone.0006609.g005
Figure 6. Foxm1 deletion after tumor initiation decreases lung
tumor expansion/progression. Experimental epFoxm1
2/2
(epFoxm1
fl/fl+Dox) and control Foxm1
fl/fl (Foxm1
fl/fl+Dox) mice were
given Dox in water to activate Cre expression after the initiation of lung
tumors by multiple urethane injections as described in Materials and
Methods. The second control group of epFoxm1
fl/fl mice was given
regular water (epFoxm1
fl/fl - Dox). All three groups of mice received six
weekly injections of urethane to induce lung tumors. A. Experimental
design of conditional deletion of Foxm1
fl/fl after tumor induction. B.
Lung tumors from experimental epFoxm1
2/2 (epFoxm1
fl/fl+Dox) mice
and control mice were counted and measured using a dissecting
microscope at 20 weeks and 28 weeks after the first urethane injection.
Deletion of Foxm1 after tumor initiation significantly reduced (p,0.05)
the total number of lung tumors at both time points.
doi:10.1371/journal.pone.0006609.g006
Foxm1 in Lung Tumors
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mice [21]. Thus, previous gain-of-function or loss-of-function
studies with ubiquitous changes in Foxm1 expression had
identified Foxm1 as an important transcription factor during lung
tumorigenesis. However, lung cancer lesions contain a heteroge-
neous population of cells, that includes epithelial, inflammatory
(macrophages, granulocytes) and stromal cells, that express
increased levels of Foxm1 [22] and may influence tumorigenesis.
Although our previous studies emphasized the essential role of
Foxm1 in lung tumorigenesis, its specific role in lung epithelial
cells, the precursors of lung adenoma or adenocarcinoma cells,
was not addressed. In the present study, deletion of Foxm1 from
respiratory epithelial cells was sufficient to significantly decrease
lung tumor formation, demonstrating the cell autonomous role of
Foxm1 in the progression of pulmonary tumors.
Two different models of lung cancer in mice were used. In the
first model, urethane acts as a complete carcinogen leading to
DNA damage with K-ras mutations and providing both initiation
Figure 7. Foxm1 is essential for lung tumor growth induced by MCA/BHT. Experimental epFoxm1
2/2 (epFoxm1
fl/fl+Dox) and control Foxm1
fl/fl
(Foxm1
fl/fl+Dox) mice were given Dox in water to activate Cre expression either 4 weeks prior to or 1 week after tumor induction/promotion with MCA/
BHT as described in Materials and Methods. The epFoxm1
fl/fl (epFoxm1
fl/fl – Dox) mice given regular water were used as controls for possible Dox-
independent recombination. All three groups of mice were injected with a single dose of MCA, followed by six weekly injections of BHT to induce lung
tumors. Mice were sacrificed at 25 weeks after MCA injection and examined for lung tumors using a dissecting microscope. A. Experimental design for
conditional deletion of Foxm1
fl/fl prior to tumor induction/promotion (left panel). epFoxm1
2/2 mice are resistant to lung tumorigenesis after MCA/BHT
treatment compared to control mice (right panel). Mean number of tumors per lung (6SD) was calculated from n=10 mouse lungs per group. B.
Experimental design for conditional deletion of Foxm1
fl/fl after tumor induction/promotion. epFoxm1
2/2 mice are resistant to lung tumorigenesis after
MCA/BHTtreatment comparedtocontrolmice(rightpanel). Meannumber oftumors perlung(6SD)wascalculatedfromn=10mouselungspergroup.
C. Decreased levels of Foxm1, TOPO-2a, PPARc and cyclin B1 mRNAs and increased levels of PPARa in epFoxm1
2/2 (epFoxm1
fl/fl+Dox) lung. qRT-PCR was
performed using total RNA from control Foxm1
fl/fl and epFoxm1
2/2 lungs. Three mice per group were used. Asterisks **indicate P values,0.001
calculated by Student T Test.
doi:10.1371/journal.pone.0006609.g007
Foxm1 in Lung Tumors
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carcinogen found in tobacco smoke [26], acts only as an initiator
(DNA damage), while BHT, acts as a tumor promoter by causing
chronic pulmonary inflammation due to necrosis of type I
epithelial cells and macrophage infiltration. Both models showed
that Foxm1 is critical for lung tumorigenesis. Consistent with these
findings, the expression of Foxm1 in colon epithelial cells [30] and
hepatocytes [18] was essential for progression of colon cancer and
hepatocellular carcinoma, respectively. Moreover, the present data
suggest that the main role of Foxm1 in epithelial cells occurs
during tumor progression/expansion. We found a similar decrease
in lung tumorigenesis regardless if Foxm1 was deleted prior to the
tumor initiation or during tumor progression. Therefore, Foxm1 is
critical for the proliferation of tumor cells during the expansion of
lung tumors.
Since lung tumors were still found in urethane-treated
epFoxm1
2/2 mice, our results suggest that a subset of lung tumor
cells can proliferate in the absence of Foxm1. Interestingly, the
epFoxm1
2/2 tumors still maintained normal expression levels of the
TTF-1 protein, a lung epithelial-specific transcription factor,
implicated in controlling cellular proliferation during embryogen-
esis and formation of non-small cell lung cancer [24]. Published
studies demonstrated that increased TTF-1 expression and
amplification of TTF-1 gene occurred in many cases of NSCLC
in human patients [31,32]. We also found that epFoxm1
2/2 tumors
displayed normal expression levels of the cell cycle promoting c-
Myc and Cyclin D1. Our results suggest that TTF-1, c-Myc and
Cyclin D1 can contribute to maintaining the low proliferation
rates in epFoxm1
2/2 tumors. Alternatively, it is also possible that
the formation of lung tumors in epFoxm1
2/2 mice may result from
Figure 8. epFoxm1
2/2 tumors displayed diminished Foxm1 staining and decreased proliferation after MCA/BHT induced
tumorigenesis. Lungs from epFoxm1
2/2 and control Foxm1
fl/fl mice, that were given Dox in water starting 4 weeks before MCA/BHT treatment,
were dissected and fixed 25 weeks after the first injection. Lung sections were used for immunohistochemistry with either Foxm1 (A–F) or KI-67
antibodies (G–L). Nuclear Foxm1 staining (shown with arrows) was detected in a subset of tumor cells (Tu in A–B) and epithelial cells of peribronchial
regions of Foxm1
fl/fl lungs (C). Although Foxm1 protein was not detected in epFoxm1
2/2 tumors, Foxm1-positive epithelial cells were still found in
alveolar region of epFoxm1
2/2 lungs (arrows in D and F). Diminished KI-67 staining was observed in epFoxm1
2/2 lungs (J–L) when compared to
control Foxm1
fl/fl lungs (G–I). Magnification is 1006. B, E, H and K are inserts from A, D, G and J.
doi:10.1371/journal.pone.0006609.g008
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PLoS ONE | www.plosone.org 9 August 2009 | Volume 4 | Issue 8 | e6609Figure 9. Foxm1 transcription factor directly binds to and induces the mouse TOPO-2a promoter region. A. Foxm1 mRNA depletion in
A549 lung adenocarcinoma cells led to decreased TOPO-2a and cyclin B1 mRNAs expression. A549 cells were mock transfected (control) or transfected
with short interfering RNA (siRNA) duplex specific for Foxm1 mRNA (siFoxm1) or with control mutant siFoxm1 duplex. Forty-eight hours after siRNA
transfection, total RNA was extracted and analyzed for Foxm1, TOPO-2a, PPARa, PPARc and cyclin B1 mRNAs by qRT-PCR. B. Western blot shows
decreased protein levels of TOPO-2a and Foxm1 in siRNA-transfected A549 cells. C. A schematic drawing of the –1.5 Kb promoter region of the
mouse TOPO-2a gene. Locations of three potential Foxm1 DNA binding sites are indicated (white boxes). D. ChIP assay demonstrated that Foxm1
protein binds to promoter regions of the TOPO-2a gene. Foxm1 binding to genomic DNA was normalized to IgG control antibodies. Diminished
binding of Foxm1 to the endogenous mouse promoter regions of the TOPO-2a gene was observed after siFoxm1 transfection in MLE-15 cells.
E. Foxm1 induced the transcriptional activity of TOPO-2a promoter. MLE-15 cells were transfected with CMV-Foxm1b expression vector and luciferase
(LUC) reporter driven by the -1.5 kb mouse TOPO-2a promoter region. CMV-empty plasmid was used as a negative control. Cotransfection of CMV-
Foxm1b and Foxm1-Luc reporter plasmids were used as a positive control. Cells were harvested at 24 hr after transfection and processed for dual LUC
assays to determine LUC activity. Transcriptional activity of the mouse TOPO-2a promoter was increased by CMV-Foxm1b transfection. A p
value,0.05 is shown with asterisk (*).
doi:10.1371/journal.pone.0006609.g009
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proliferation defects in Foxm1-deficient lung tumor cells.
The present study demonstrated that TOPO-2a was decreased
after deletion of Foxm1 during pulmonary tumorigenesis and it
was shown that Foxm1 directly induces the TOPO-2a promoter
activity. Type II topoisomerases are ubiquitous enzymes that play
essential roles in regulating DNA under- and over-winding, and
resolving knots and tangles in the genetic material through
transient double-stranded breaks [33]. Because TOPO-2a gener-
ates DNA strand breaks, it has the potential to fragment the
genome every time it functions and to cause significant genotoxic
damage. TOPO-2a levels increase during the cell cycle, peaking in
G2/M [34], in close correlation with the expression levels of
Foxm1 transcription factor [7]. In the present study, we
established that TOPO-2a expression was significantly decreased
in Foxm1 deficient lung tumors as well as in A549 human lung
adenocarcinoma cells transfected in vitro with Foxm1-specific
siRNA. Chromatin immunoprecipitation assay demonstrated that
Foxm1 protein directly binds to the mouse TOPO-2a promoter,
suggesting that Foxm1 is a direct transcriptional activator of
TOPO-2a gene. This is an important finding that can be used for
designing the new therapeutic strategies to treat lung cancer.
Deletion of Foxm1 in lung epithelial cells increased PPARa
expression during tumorigenesis in vivo. PPARa mRNA was also
increased in Foxm1-depleted A549 lung adenocarcinoma cells in
vitro. PPARa is the member of the nuclear hormone receptor
superfamily that acts as a ligand-activated transcription factor.
Recent studies indicate that PPARa expression is increased in
mouse or human medullablastoma cells, leading to the gradual
accumulation of cells in G1 and G2/M phases of the cell cycle and
inhibition of cell proliferation [35]. Since accumulation of cells in
G1 and G2/M and inhibition of cell proliferation are main
characteristics of Foxm1 deficiency [25], this recent data is
consistent with our findings that increased PPARa mRNA in
Foxm1 deficient tumors correlated with inhibition of cell
prolifetartion. The other study showed that incidence of DEHP-
induced hepatocellular carcinomas in PPARa-null mice was
significantly higher than in wild type mice [36], suggesting
negative relationship between PPARa expression and cell
proliferation. Therefore, increased PPARa expression in Foxm1-
deficient epithelial cells may contribute to reduced tumorigenesis
in epFoxm1
2/2 mice.
In summary, deletion of Foxm1 in respiratory epithelial cells
prior to or even after tumor initiation caused a striking decrease in
the number and size of lung tumors. Decreased tumor formation
in epFoxm1
2/2 lungs was associated with diminished proliferation
of tumor cells. Micro-dissected tumors from epFoxm1
2/2 lungs
showed significant decrease in TOPO-2a mRNA expression.
Foxm1 induced TOPO-2a expression in A549 lung adenocarcino-
ma cells and directly bound to the TOPO-2a promoter region. The
present data demonstrates that Foxm1 expression in respiratory
epithelial cells is required for progression/expansion of chemically-
induced lung cancer in vivo and provides support for the concept
that Foxm1 functions in a cell autonomous manner during
pulmonary carcinogenesis. Our studies suggest that Foxm1
represents a potential therapeutic target in treatment of NSCLC
lung cancers.
Materials and Methods
Transgenic mice
The generation of Foxm1
flox/flox (Foxm1
fl/fl) mice was described
previously [11]. The Foxm1
fl/fl mice were bred with SPC–rtTA
tg/2/
TetO-Cre
tg/tg mice [23] to generate the SPC–rtTA
tg/2/TetO-Cre
tg/2/
Foxm1
fl/fl triple transgenic mice (epFoxm1
fl/fl). Only male mice were
used for tumor studies. To induce Cre expression in respiratory
epithelium and produce epFoxm1
2/2 mice, doxycycline (Dox; 1% in
drinking water) was given to 8 week old mice. Four weeks later, lung
tumors were induced by urethane or MCA/BHT. Dox treatment
was continued through the whole experiment (tumor induction and
progression studies). In another series of experiments Dox was given
starting 1 week after the last urethane or BHT injections until the
day of tissue harvest (tumor progression studies). Dox-treated
Foxm1
fl/fl male littermates lacking either the SPC–rtTA, the TetO-Cre
or both transgenes were used as controls. Further controls included
Dox-treated SPC–rtTA
tg/2/TetO-Cre
tg/2/Foxm1
fl/+ male mice and
SPC–rtTA
tg/2/TetO-Cre
tg/2/Foxm1
fl/fl male mice without Dox
treatment (epFoxm1
fl/fl – Dox group). Animal studies were reviewed
and approved by the Animal Care and Use Committee of
Cincinnati Children’s Hospital Research Foundation.
Tumor induction protocols
Urethane protocol. Control and epFoxm1
2/2 male mice
were injected i.p. with 1 mg/g of body weight of urethane (Sigma,
St. Louis, MO; diluted in saline) once a week for 6 consecutive
weeks and tumors were counted and examined 20 and 28 weeks
after the initial injection using a dissecting microscope.
Individually microdissected lung tumors were used to prepare
total RNA with RNA-STAT-60 (Tel-Test ‘‘B’’ Inc. Friendswood,
TX). Lung tissues were fixed and embedded in paraffin blocks.
MCA/BHT protocol. MCA (Sigma, St. Louis, MO), a
polycyclic aromatic hydrocarbon found in tobacco smoke which
serves as a tumor initiator, was given as a single i.p. dose of 15 mg/
g of body weight, followed by six weekly i.p. injections with BHT,
a known tumor promoter, (200 mg/g of body weight; Sigma, St.
Louis, MO). MCA and BHT were solubilized in corn oil. Mice
were sacrificed at 25 weeks following MCA injection and
examined for lung tumors using a dissecting microscope.
Immunohistochemical staining and in situ hybridization
Paraffin (5 mm) sections were stained with hematoxylin and eosin
(H&E) for morphological examination or immunostained with
antibodies against KI-67 (1:500; clone Tec-3, Dako), Cre (1:30,000;
no. 69050–3, Novagen), SPC (1;1,500; AB-3428, Chemicon
International), CCSP (1:1,000; a gift from B. Stripp, Duke
University), TTF-1 (1:3,000, gift of Dr. DiLauro, Stazione
Zoologica, Naples, Italy) or Foxm1 (1:2000; clone K-19; Santa
Cruze Biotechnology, Santa Cruze, CA). Antibody-antigen com-
plexesweredetectedusingbiotinylatedsecondaryantibodyfollowed
by avidin-horseradish peroxidase (HRP) complex, and DAB
substrate (all from Vector Lab, Burlingame, CA) as described
[21]. Sections were counterstained with nuclear fast red (Vector
Labs, Burlingame, CA). Lung sections were also used for in situ
hybridization with 35S-labeled antisense riboprobe specific to
1649–1947 bp region of the mouse Foxm1 mRNA as described [7].
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was prepared from microdissected lung tumors of
epFoxm1
2/2 or control Foxm1
fl/fl mice, or from A549 human lung
adenocarcinoma cells (purchased from ATCC, Manassas, VA) and
analyzed by qRT-PCR using the StepOnePlus Real-Time PCR
system (Applied Biosystems, Foster City, CA). Samples were
amplified with Taqman Gene Expression Master Mix (Applied
Biosystems) combined with inventoried Taqman gene expression
assays: mouse Foxm1, Mm00514924_m1; mouse cyclinB1,
Mm00838401_g1; mouse PPARa, Mm00440939_m1; mouse
PPARc, Mm00440945_m1; mouse TOPO-2a, Mm00495703_m1;
mouseb-Actin, Mm00607939_s1; mouse c-Myc, Mm00487804_m1;
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Mm00432359_m1; mouse Vegfa, Mm00437304_m1; mouse TTF-
1, Mm00447558_m1; human FoxM1, Hs00133543_m1; human
Cyclin B1, Hs00259126_m1; human PPARa, Hs00231982_m1;
human PPARc, Hs00234592_m1; human TOPO-2a,
Hs01032127_g1; human b–Actin, Hs99999903_m1. Reactions were
analyzed in triplicates and expression levels were normalized to b-
Actin.
siRNA transfection
We transfected 100 nmol/L of either Foxm1-specific siRNA
(siFoxm1; Dharmacon Research, Lafayette, CO) or mutant
control siFoxm1 into human A549 lung adenocarcinoma cells
(purchased from ATCC) using Lipofectamine
TM 2000 reagent
(Invitrogen) in serum free tissue culture media as described
previously [13,20]. Forty-eight hours after transfection, the A549
cells were used to prepare total RNA.
Western blot
Nuclear protein extracts were prepared from A549 adenocar-
cinoma cell lines at 48 hours following siRNA transfection or
mock transfection using Nuclear/Cytosol Fractionation kit (K266-
100, BioVision, Mountain View, CA) following protocols provided
by the manufacturer, and Western blot analysis was done as
described previously [13]. The rabbit anti-Foxm1 antibody
(1:1000; clone C-20; Santa Cruze Biotechnology, Santa Cruze,
CA) and mouse anti-TOPO-2a antibody (1:2500; cat#
MAB4197; Chemicon) were used. The signals from the primary
antibody were amplified by HRP-conjugated anti-mouse IgG (Bio-
Rad, Hercules, CA) and detected with Enhanced Chemilumines-
cence Plus (Amersham Pharmacia Biotech, Piscataway, NJ)
followed by autoradiography.
Cotransfection studies and chromatin
immunoprecipitation (ChIP) assay
We used PCR of mouse genomic DNA to amplify the -1544/
+17 region of the mouse TOPO-2a promoter (Gene Bank Number
NT_165773.2) using following primers: 59-GGG GTA CCC CCC
CCC AAA AAA AAA AAC ACC-39 and 59-CGA CGC GTA
AAG CGA CAA AAC CAG CGG-39. The PCR product was
cloned into pGL3-Basic firefly luciferase (LUC) reporter plasmid
(Promega) and then verified by DNA sequencing (Gene Bank
Number NT_165773.2). We transfected mouse lung epithelial
MLE-15 cells [37] with either CMV-Foxm1b (Gene Bank number
NM_008021) or control CMV-empty expression plasmids, as well
as with LUC reporters driven by –1.5 kb mouse TOPO-2a
promoter. CMV-Renilla was used as an internal control to
normalize transfection efficiency. Dual luciferase assay (Promega)
was performed 24 hours after transfection as described [37].
Untransfected or siRNA-transfected mouse lung epithelial
MLE-15 cells [37] were cross-linked by addition of formaldehyde,
sonicated and used for the immunoprecipitation with Foxm1
rabbit polyclonal antibodies (H-300, Santa Cruz, CA) as described
previously [25]. DNA fragments were 500 bp – 1000 bp. Reverse
cross-linked ChIP DNA samples were subjected to qRT-PCR
using the oligonucleotides specific to -1596/-1465 bp region of
mouse TOPO-2a (59- ACTGCCAGGACTACACAGAGGAAC-
39 and 59-GGAGGGTGACTTCAATGCTTAGG -39). DNA
binding was normalized to control ChIP DNA samples, which
were immunoprecipitated using control rabbit serum.
Statistical analysis
We used Microsoft Excel Program to calculate SD and
statistically significant differences between samples using the
Student T Test. P values,0.05 were considered statistically
significant.
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